Trial NCT04796896
Publication Creech CB, N Engl J Med, 2022
Primary outcome on the report: 1. Solicited local and systemic ARs through 7 days after each injection; 2. Unsolicited AEs through 28 days after each injection; 3. MAAEs through the entire study period; 4. SAEs through the entire study period; 5. AESIs, including MIS-C and myocarditis and/or pericarditis, through the entire study period; 6. The proportion of participants with a serum antibody level at day ≥57 antibody threshold of protection; 7. The GM value of serum antibody level and seroresponse rate from Study P204 vaccine recipients at day 57 compared with those from young adult (18≤25 years of age) vaccine recipients (day 57) in the clinical endpoint efficacy trial

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.